Skip to main content
. 2013 May 31;2013(5):CD004525. doi: 10.1002/14651858.CD004525.pub2

Comparison 43. Adverse events within 12 months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD).

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1 Alopecia 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
1.1 Etanercept 10 mg SC twice weekly 1 425 Risk Ratio (M‐H, Fixed, 95% CI) 0.58 [0.31, 1.09]
1.2 Etanercept 25 mg SC twice weekly 1 424 Risk Ratio (M‐H, Fixed, 95% CI) 0.50 [0.26, 0.97]
2 Abdominal pain 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
2.1 Etanercept 10 mg SC twice weekly 1 425 Risk Ratio (M‐H, Fixed, 95% CI) 1.09 [0.63, 1.90]
2.2 Etanercept 25 mg SC twice weekly 1 424 Risk Ratio (M‐H, Fixed, 95% CI) 0.95 [0.54, 1.69]
3 Asthenia 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
3.1 Etanercept 10 mg SC twice weekly 1 425 Risk Ratio (M‐H, Fixed, 95% CI) 0.73 [0.42, 1.28]
3.2 Etanercept 25 mg SC twice weekly 1 424 Risk Ratio (M‐H, Fixed, 95% CI) 1.05 [0.64, 1.73]
4 Back pain 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
4.1 Etanercept 10 mg SC twice weekly 1 425 Risk Ratio (M‐H, Fixed, 95% CI) 1.04 [0.48, 2.27]
4.2 Etanercept 25 mg SC twice weekly 1 424 Risk Ratio (M‐H, Fixed, 95% CI) 1.92 [0.98, 3.78]
5 Diarrhoea 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
5.1 Etanercept 10 mg SC twice weekly 1 425 Risk Ratio (M‐H, Fixed, 95% CI) 1.00 [0.61, 1.66]
5.2 Etanercept 25 mg SC twice weekly 1 424 Risk Ratio (M‐H, Fixed, 95% CI) 1.16 [0.72, 1.89]
6 Dizziness 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
6.1 Etanercept 10 mg SC twice weekly 1 425 Risk Ratio (M‐H, Fixed, 95% CI) 0.45 [0.22, 0.93]
6.2 Etanercept 25 mg SC twice weekly 1 424 Risk Ratio (M‐H, Fixed, 95% CI) 1.09 [0.64, 1.88]
7 Dyspepsia 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
7.1 Etanercept 10 mg SC twice weekly 1 425 Risk Ratio (M‐H, Fixed, 95% CI) 1.04 [0.59, 1.85]
7.2 Etanercept 25 mg SC twice weekly 1 424 Risk Ratio (M‐H, Fixed, 95% CI) 1.25 [0.72, 2.16]
8 Ecchymosis 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
8.1 Etanercept 10 mg SC twice weekly 1 425 Risk Ratio (M‐H, Fixed, 95% CI) 0.81 [0.44, 1.47]
8.2 Etanercept 25 mg SC twice weekly 1 424 Risk Ratio (M‐H, Fixed, 95% CI) 0.86 [0.47, 1.55]
9 Headache 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
9.1 Etanercept 10 mg SC twice weekly 1 425 Risk Ratio (M‐H, Fixed, 95% CI) 0.92 [0.67, 1.27]
9.2 Etanercept 25 mg SC twice weekly 1 424 Risk Ratio (M‐H, Fixed, 95% CI) 0.82 [0.58, 1.14]
10 Influenza‐like syndrome 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
10.1 Etanercept 10 mg SC twice weekly 1 425 Risk Ratio (M‐H, Fixed, 95% CI) 0.83 [0.48, 1.46]
10.2 Etanercept 25 mg SC twice weekly 1 424 Risk Ratio (M‐H, Fixed, 95% CI) 1.09 [0.65, 1.82]
11 Injection site haemorrhagia 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
11.1 Etanercept 10 mg SC twice weekly 1 425 Risk Ratio (M‐H, Fixed, 95% CI) 1.49 [0.88, 2.52]
11.2 Etanercept 25 mg SC twice weekly 1 424 Risk Ratio (M‐H, Fixed, 95% CI) 1.45 [0.85, 2.46]
12 Injection site reaction 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
12.1 Etanercept 10 mg SC twice weekly 1 425 Risk Ratio (M‐H, Fixed, 95% CI) 4.11 [2.46, 6.87]
12.2 Etanercept 25 mg SC twice weekly 1 424 Risk Ratio (M‐H, Fixed, 95% CI) 5.04 [3.05, 8.35]
13 Mouth ulcers 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
13.1 Etanercept 10 mg SC twice weekly 1 425 Risk Ratio (M‐H, Fixed, 95% CI) 0.45 [0.24, 0.84]
13.2 Etanercept 25 mg SC twice weekly 1 424 Risk Ratio (M‐H, Fixed, 95% CI) 0.35 [0.18, 0.70]
14 Nausea 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
14.1 Etanercept 10 mg SC twice weekly 1 425 Risk Ratio (M‐H, Fixed, 95% CI) 0.49 [0.33, 0.73]
14.2 Etanercept 25 mg SC twice weekly 1 424 Risk Ratio (M‐H, Fixed, 95% CI) 0.59 [0.41, 0.86]
15 Rash 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
15.1 Etanercept 10 mg SC twice weekly 1 425 Risk Ratio (M‐H, Fixed, 95% CI) 0.69 [0.46, 1.02]
15.2 Etanercept 25 mg SC twice weekly 1 424 Risk Ratio (M‐H, Fixed, 95% CI) 0.52 [0.34, 0.81]
16 Rhinitis 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
16.1 Etanercept 10 mg SC twice weekly 1 425 Risk Ratio (M‐H, Fixed, 95% CI) 1.25 [0.80, 1.95]
16.2 Etanercept 25 mg SC twice weekly 1 424 Risk Ratio (M‐H, Fixed, 95% CI) 1.08 [0.68, 1.72]
17 Sinusitis 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
17.1 Etanercept 10 mg SC twice weekly 1 425 Risk Ratio (M‐H, Fixed, 95% CI) 0.81 [0.51, 1.28]
17.2 Etanercept 25 mg SC twice weekly 1 424 Risk Ratio (M‐H, Fixed, 95% CI) 0.58 [0.35, 0.97]
18 Skin infection 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
18.1 Etanercept 10 mg SC twice weekly 1 425 Risk Ratio (M‐H, Fixed, 95% CI) 1.04 [0.60, 1.83]
18.2 Etanercept 25 mg SC twice weekly 1 424 Risk Ratio (M‐H, Fixed, 95% CI) 1.33 [0.79, 2.26]
19 Upper respiratory tract infection 2   Risk Ratio (M‐H, Random, 95% CI) Subtotals only
19.1 Etanercept 10 mg SC twice weekly 1 425 Risk Ratio (M‐H, Random, 95% CI) 0.71 [0.54, 0.93]
19.2 Etanercept 25 mg SC twice weekly 2 577 Risk Ratio (M‐H, Random, 95% CI) 1.02 [0.68, 1.52]